Request Trial
dmitryintag
dmitryintag / iStockphoto.com
30 August 2017AmericasWenhua Yu, Stephen Maebius and Tianran Yan

Data analysis: the highs and lows of generic-filed IPRs

We reviewed a sub-group of 204 inter partes reviews (IPRs) filed by generic drug companies against pharmaceutical patents to assess Patent Trial and Appeal Board (PTAB) outcomes and key trends in dealing with this technology field. The study captured IPR filings by 14 of the most active generic petitioners among the world’s top-20 generic drug companies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
From migraine drugs to COVID vaccine spats, US lawsuits pile up
9 January 2026   A busy week in US courts saw major pharma companies and biotech firms move to protect key therapies and research tools, with new lawsuits over migraine and cancer drug generics, and alleged misuse of COVID-19 vaccine tech.
Americas
Insulin pump rivals face off in major trade secrets dispute hearing
8 January 2026   Important questions about when companies must act on suspicions of theft and whether damages can stack with injunctions were raised in a dispute that has already sent ripples across med tech.
Americas
Bayer enters COVID-19 vaccine row with three suits against major drugmakers
8 January 2026   Crop science division alleges that vaccine developers used patented mRNA stability technology in shots that earned them around $140 billion in global sales.


Editor's picks

Deadline extended: Who are the world’s best in-house counsel?
Europe
Deadline extended: Who are the world’s best in-house counsel?
9 January 2026

Editor's picks

Europe
Deadline extended: Who are the world’s best in-house counsel?
9 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025
Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025

More features

From migraine drugs to COVID vaccine spats, US lawsuits pile up
How AI will be shaped by legal and regulatory developments in 2026
Deadline extended: Who are the world’s best in-house counsel?
Insulin pump rivals face off in major trade secrets dispute hearing
Bayer enters COVID-19 vaccine row with three suits against major drugmakers
Merchant & Gould hires 13 attorneys to open new Boston office
Novo Nordisk secures China win ahead of key patent expiration
Bird & Bird targets Nordic life sciences growth with regulatory hire